Lantern Pharma (LTRN) grants director new stock options awards units

Rhea-AI Filing Summary

Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.

On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silberstein David S.

(Last) (First) (Middle)

1920 MCKINNEY AVENUE, 7TH FLOOR

(Street)

DALLAS TX 75201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lantern Pharma Inc. [ LTRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.49	01/09/2026		A		25,000		(1)	01/08/2036	Common Stock	25,000	$0.00	25,000	D
Stock Option (Right to Buy)	$3.49	01/09/2026		A		17,307		(2)	01/08/2036	Common Stock	17,307	$0.00	17,307	D

Explanation of Responses:

1. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.

2. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.

	/s/ David S. Silberstein	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lantern Pharma (LTRN) report for David S. Silberstein?

The company reported that director David S. Silberstein received two grants of stock options to buy Lantern Pharma common stock on January 9, 2026 as equity compensation.

How many stock options did the Lantern Pharma director receive and at what price?

He received one grant of 25,000 stock options and another of 17,307 stock options, each with an exercise price of $3.49 per share for Lantern Pharma common stock.

What are the vesting terms of the Lantern Pharma director’s new stock options?

The 25,000 options vest in equal monthly increments over 24 months starting February 9, 2026. The 17,307 options vest in equal monthly increments over 12 months, also beginning February 9, 2026.

Under which plan were the Lantern Pharma stock options granted?

Both option grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan, as stated in the footnotes.

Does David S. Silberstein hold these Lantern Pharma options directly or indirectly?

The filing shows that all reported stock options are held directly by David S. Silberstein, with no indirect ownership entity disclosed.

Is the Lantern Pharma director considered a 10% owner in this insider filing?

No. The reporting information identifies David S. Silberstein as a director of Lantern Pharma Inc., not as a 10% owner or officer.